Shares of Hims & Hers Health (NYSE: HIMS) surged over 23% in intraday trading on Tuesday, following the announcement of a strategic, long-term collaboration with Novo Nordisk A/S (NYSE: NVO). The partnership will enable the telehealth company to offer Novo Nordisk’s widely prescribed obesity treatment, Wegovy, through its digital platform.
As part of the partnership, Hims & Hers will offer patients in the United States access to a comprehensive Wegovy package, which includes all available dosage levels, at a standardized monthly cost starting at $599, effective this week.
Both companies emphasized their shared objective of advancing a roadmap that integrates Novo Nordisk’s innovative therapies with Hims & Hers’ scalable digital healthcare infrastructure, aiming to expand access to effective and affordable obesity care.
Hims & Hers also mentioned that its platform would continue to offer a wider range of weight management solutions, including alternative medications, oral kits, protein and nutrition packages, and clinically-backed care plans.
Earlier this month, Hims & Hers revealed plans to start distributing Eli Lilly’s (NYSE: LLY) weight-loss medication, as part of its broader strategy to diversify treatment options and mitigate risks associated with potential regulatory limitations on semaglutide-based therapies like Wegovy.
Hims & Hers shares had faced a downturn in February after the U.S. Food and Drug Administration (FDA) removed Wegovy and the diabetes drug Ozempic—both containing the active ingredient semaglutide—from its shortage list. These shortages had previously allowed Hims & Hers to distribute more affordable versions of semaglutide, but their removal curtailed this practice.
Shares of Hims & Hers Health (NYSE: HIMS) are continuing to rise in pre-market trading on Wednesday, up 1.63% at $35.61.
Salman Akhtar is a finance, stocks, and technology journalist with years of experience across various news organizations. He has contributed his expertise to outlets such as 24NewsHD, TrimFeed, The Voice Pakistan, and TheTechBasic. Salman is passionate about making complex topics accessible to a broad audience. His dedication to delivering accurate and timely information has established him as a trusted voice in the industry. Read Full Bio
